There is increasing interest in intestinal infection as a route of viral spread (Guo et al., 2021); among people taking ACE inhibitors, associated increases in small intestine ACE2 could potentially increase the risk of SARS-CoV-2 viral infection. The gene discussed is ACE; the disease is COVID-19.